Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab and Radiation Therapy in Metastatic Pancreatic Cancer
NCT02885727Phase 2Withdrawn
- Sponsor
- University of Maryland, Baltimore
- Start
- Jul 2017
- Primary completion
- Dec 2020
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
01
Overview
A Phase 2 trial of durvalumab in pancreatic adenocarcinoma (PDAC), sponsored by University of Maryland, Baltimore. Planned start Jul 2017; status: withdrawn.
02
Drugs
durvalumab
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02885727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02885727.